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Abstract
Fluticasone furoate (FF) – USAN approved name, a new topically active glucocorticoid has been
recently identified. The aim of this study was to characterise the binding affinity of this compound
to the human lung glucocorticoid receptor in relation to other glucocorticoids. Additionally, we
sought to determine the binding behaviour of fluticasone furoate to human lung tissue. The
glucocorticoid receptor binding kinetics of fluticasone furoate revealed a remarkably fast
association and a slow dissociation resulting in a relative receptor affinity (RRA) of 2989 ± 135 with
reference to dexamethasone (RRA: 100 ± 5). Thus, the RRA of FF exceeds the RRAs of all currently
clinically used corticosteroids such as mometasone furoate (MF; RRA 2244), fluticasone propionate
(FP; RRA 1775), ciclesonide's active metabolite (RRA 1212 – rat receptor data) or budesonide
(RRA 855). FP and FF displayed pronounced retention in human lung tissue in vitro. Lowest tissue
binding was found for MF. There was no indication of instability or chemical modification of FF in
human lung tissue. These advantageous binding attributes may contribute to a highly efficacious
profile for FF as a topical treatment for inflammatory disorders of the respiratory tract.
Background
A new topically active glucocorticoid, fluticasone furoate
(FF, GW685698X), has been recently identified (Figure 1)
and is being progressed for the treatment of respiratory
diseases. Fluticasone furoate (FF) shares structural similar-
ities with fluticasone propionate (FP) with the exception
of the substitution of the 17-α hydroxyl group. While this
position is esterified with propionic acid in FP, FF carries
a 2-furoate ester moiety.
For topically applied glucocorticoids, it is favorable to
combine high local efficacy with low systemic exposure.
An enhanced affinity for lung tissue may prolong resi-
dence time in the lung and minimise systemic effects.
Therefore, a high receptor affinity and a high retention in
the target tissue should be paralleled by rapid and com-
plete hepatic metabolism of the glucocorticoid to inactive
derivatives. We previously described the receptor binding
affinity of FP and MF as well as their retention in lung tis-
sue in vitro [1-4]. Both FP and MF have high affinities for
the human lung glucocorticoid receptor. The relative
receptor affinity (RRA) of FP is about 1800 compared to
the reference compound dexamethasone (RRA= 100), the
RRA of MF is about 2250.
The aim of this study was to characterise the binding affin-
ity of the novel compound FF to the glucocorticoid recep-
tor in relation to other glucocorticoids. Therefore, we
isolated human lung glucocorticoid receptors from
human lung tissue and determined the binding affinity of
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these glucocorticoids by the kinetic method described ear-
lier [1]. Additionally, we sought to determine the reten-
tion of FF in human lung tissue.
Methods
Chemicals and reagents
[3H]-Dexamethasone was obtained from Amersham
(Freiburg, Germany), dexamethasone was purchased
from Merck (Darmstadt, Germany). [3H]-Fluticasone
furoate, FP, MF, FF, ciclesonide (Cicle) and its active
metabolite desisobutyryl-ciclesonide (des-Cicle), beclom-
ethasone-17, 21-dipropionate (BDP) and its metabolite
beclomethasone-17-monopropionate (17-BMP) and
beclomethasone-21-monopropionate (21-BMP) were
generous gifts from GlaxoSmithKline (Greenford, Eng-
land). The origin of all other glucocorticoids mentioned is
described in [5]. Dimethyl-2-2-dichlorvinylphosphate
(dichlorvos) was purchased from Riedel de Haën (Seelze,
Germany), DL-dithiothreitol (DTT) from Sigma-Aldrich-
Chemie (Taufkirchen, Germany). Complete™ (combina-
tion of different protease inhibitors) was obtained from
Roche Applied Science (Mannheim, Germany), Norit A
from Serva (Heidelberg, Germany). Diethylether (HPLC
grade) was purchased from Fluka (Buchs, Switzerland)
and acetonitrile (ACN, HPLC gradient grade) from Fisher
Scientific, (Schwerte, Germany). Water from a Millipore
water purification unit was used. All other chemicals were
obtained from E. Merck (Darmstadt, Germany).
Buffer solutions
Buffer solution G contained 10 mM TRIS, 10 mM
Na2MoO4, 30 mM NaCl, 10 % glycerol (pH 7.4). Buffer
solution A contained 4 mM DTT, 5 mM dichlorvos and 1
mM Complete™ in 100 mL buffer solution G. Krebs-
Ringer-HEPES buffer (pH 7.4) consisted of 118 mM NaCl,
4.84 mM KCl, 1.2 mM KH2PO4, 2.43 mM MgSO4, 2.44
mM CaCl2 × 2 H2O and 10 mM HEPES.
Source and handling of human specimen
Human lung tissue resection material was obtained from
patients with bronchial carcinomas who gave informed
consent. Cancer-free tissue was used for the experiments.
None of the patients was treated with glucocorticoids for
the last 4 weeks prior to surgery. Tissue samples were used
immediately for tissue metabolism studies to retain full
enzymatic activity. For other experiments, tissue samples
were shock frozen in liquid nitrogen after resection and
stored at -70°C until usage. To collect sufficient material
for the experiments tissue samples of three or more
patients were pooled.
Plasma samples were obtained from healthy volunteers
who gave informed consent. Samples were used immedi-
ately for metabolism studies to retain full enzymatic activ-
ity. For desorption and other experiments, plasma
samples were shock frozen in liquid nitrogen and stored
at -70°C until usage.
Preparation of lung cytosol for receptor binding 
experiments
Human lung tissue was deep frozen immediately after
resection and stored in liquid nitrogen. Frozen tissue was
pulverized and homogenized in three aliquots buffer
solution A with an Ultra Turrax mixer (Janke and Kunkel,
Staufen, Germany) in an ice bath. Thereafter the diluted
cytosol was centrifuged for 1 hr at 105,000 × g at 4°C
(Ultracentrifuge L8-55 M, Beckman Instruments Irvine,
California). The cytosol was stored in aliquots at -70°C.
The protein concentration of the cytosol was determined
according to the method of Lowry et al. [6]. Concentra-
tion of glucocorticoid receptors in the cytosol was 30–60
fmol/mg protein.
Kinetics of receptor binding of glucocortiocids
The receptor binding experiments were performed accord-
ing to the procedure described earlier [1] based on [7-9].
A. Determination of receptor number in the cytosol and calculation 
of equilibrium dissociation rate constant
Various dilutions of [3H]-dexamethasone in buffer solu-
tion G (6 × 10-7 to 1.2 × 10-8 mol/L) were prepared. For
elucidation of non-specific binding a solution of dexame-
thasone (1.2 × 10-5 mol/L) in buffer solution G was used.
For the assay of non-specific binding (Bns in [mol/L]), 20
Structural formulae of the new glucocorticoid fluticasone  furoate in comparison with fluticasone propionate and  mometasone furoate Figure 1
Structural formulae of the new glucocorticoid fluticasone 
furoate in comparison with fluticasone propionate and 
mometasone furoate.
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µL of [3H]-dexamethasone and 20 µL of the unlabelled
compound were added to 200 µL of cytosol, were mixed
in glass vials and incubated for 18 to 20 h at 0–4°C. The
assay for total binding (Bt in [mol/L]) was carried out
accordingly, but the unlabelled glucocorticoid was
replaced by buffer solution G. To determine the total [3H]-
glucocorticoid concentration (T), 20 µL of the mixture
were used for scintillation counting. After incubation, 200
µL of each incubation mixture were added to 200 µL sus-
pension of activated charcoal (2 % Norit A in buffer solu-
tion G), incubated for 10 min on ice and centrifuged for 5
min between 0–4°C. For scintillation counting 200 µL of
the supernatant were used. Scintillation counting was per-
formed with a Rackbeta 1214 LKB from Wallac (Freiburg,
Germany) using Emulsifier-Safe™ from Packard Bio-
science (Groningen, Netherlands).
Receptor concentration (R0) of the cytosol was calculated
by the method of Scatchard [10] according the equation:
with BS being the specific binding of the labelled dexame-
thasone in [mol/L], H being the unbound labelled gluco-
corticoid, and KD being the equilibrium dissociation rate
constant. BS and H were indirectly determined using the
equations:
[Bs] = [Bt] - [Bns]
[H] = [T] - [Bt]
The Scatchard plot revealed the equilibrium dissociation
rate constant KD (slope of the straight line) and the recep-
tor number R0 in mol receptors per mg total protein of the
cytosol (interception of the straight line with the x-axis).
B. Determination of association rate constants kAss (= k1)
For the determination of the association rate constant, the
cytosol was incubated with different concentrations of
[3H]-glucocorticoid in the absence and presence of excess
unlabelled glucocorticoid. For the assay of non-specific
binding, 10 parts of cytosol, 1 volume part of [3H]-gluco-
corticoid (1.2 × 10-7 mol/L) and 1 volume part of cold glu-
cocorticoid (1.2 × 10-4 mol/L) were mixed in glass vials
and incubated at 20°C. The assay for total binding was
carried out accordingly, but the unlabelled glucocorticoid
(1.2 × 10-4 mol/L) was replaced by buffer G. To determine
the total [3H]-glucocorticoid concentration, aliquots of
the incubation mixtures were used for scintillation count-
ing. At intervals, 200 µL incubation mixture were mixed
with 200 µL suspension of Norit A, incubated for 10 min
on ice and centrifuged for 5 min between 0–4°C. For scin-
tillation counting 200 µL of the supernatant were used.
The association rate constant (kAss = k1) of the cytosol was
calculated according the equation:
with Gt being the concentration of unbound labelled glu-
cocorticoid at time t, Rt being the concentration of free
receptors at time t, G0  being the concentration of
unbound labelled glucocorticoid at time t = 0, R0 being
the concentration of free receptors at time t = 0 and t being
the time of incubation. G0 and Gt were indirectly deter-
mined using the equations:
[G0] = [T] - [Bns,0] and [Gt] = [T] - [Bns,t]
To linearize the calculated data points a Zt-value was cal-
culated for each time point of measurement taking the
dilution factor of the cytosol and the receptor concentra-
tion into account:
The Zt-values were plotted against time t and a linear
regression was performed. The slope of the straight line
(kAss = k1) and the coefficient of correlation r were calcu-
lated based on a minimum of four data points. The coef-
ficient of correlation was always higher than r = 0.975.
C. Determination of dissociation rate constants kDiss(= k-1)
For determination of the dissociation rate constant, 10
volume parts cytosol and 1 volume part [3H]-glucocorti-
coid solution (6 × 10-7 mol/L) were incubated for 18–20
h between 0–4°C (mixture 1). To determine the non-spe-
cific binding, 10 volume parts of cytosol, 1 volume part of
[3H]-glucocorticoid solution (6 × 10-7 mol/L) and 1 part
of unlabelled glucocorticoid (3 × 10-4 mol/L) were incu-
bated for 18–20 h between 0–4°C (mixture 2). Incuba-
tion mixtures were subsequently brought to a temperature
of 20°C. One volume part of unlabelled glucocorticoid (3
× 10-4 mol/L) was added to mixture 1. At intervals 200 µL
each of the mixtures 1 and 2 were mixed with 200 µL
Norit A suspension, incubated at 0–4°C for 10 min and
thereafter centrifuged for 5 min at 0–4°C. The superna-
tant was used for scintillation counting. The first order
rate constant was calculated according:
with Bs,t being the specific binding of the labelled com-
pound at time t, Bs,0 being the specific binding of the
labelled compound at time t = 0. Since the specific bind-
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ing was determined indirectly (see A) the equation can be
rewritten as:
The Bs,t-values were plotted semi-logarithmical against
time t and a linear regression was performed. The slope of
the straight line (kDiss = k-1) and the coefficient of correla-
tion r were calculated based on a minimum of six data
points. The coefficient of correlation was always higher
than r = 0.975.
Equilibrium dissociation constant (KD) was calculated for
each glucocorticoid based on association and dissociation
rate constants:
Relative receptor affinities (RRA) for glucocorticoids (GC)
were calculated with reference to dexamethasone (Dexa):
Stability of fluticasone furoate (FF) in fresh human lung 
tissue in vitro
Fluticasone furoate (FF) (0.3 µg/mL) was incubated in 10
ml Krebs-Ringer-HEPES buffer with lung tissue pieces at
37°C shielded from light in a thermostatically controlled
shaking water bath GFL 1083 (Burgwedel, Germany).
Incubations were performed in the presence and absence
of dichlorvos (1 mg/mL). Over 24 hours, samples of 1.0
mL tissue-free supernatant were taken and immediately
stored at -20°C until analysis. The incubation medium
was replenished by buffer which was pre-temperated to
37°C. In case of incubations with dichlorvos the medium
used for replenishment contained the esterase inhibitor.
Adsorption of glucocorticoids to lung tissue
Lung tissue was washed in Krebs-Ringer-HEPES buffer
(pH 7.4) and sliced into pieces of 1 mm3. For each bind-
ing experiment approximately 0.5 g of lung tissue was
used. Adsorption of glucocorticoids (0.3 µg/mL) to
human lung tissue was determined as described earlier
[3]. Briefly, lung tissue pieces were suspended under gen-
tle shaking for 1 h at 37°C in 20 ml Krebs-Ringer-HEPES
buffer containing 0.3 µg/ml of the glucocorticoid. 2.0 mL
samples were taken and stored at -20°C until analysis. The
volume withdrawn was replaced with fresh buffer of
37°C. Only glass lab ware was used for these experiments
to avoid any non-specific binding effects of the highly
lipophilic compounds to plastic material. For control,
blank samples with glucocorticoid-containing buffer, but
no tissue, were incubated under the same experimental
conditions (1 h at 37°C, in Krebs-Ringer-HEPES buffer)
and analyzed for non-specific adsorption of the glucocor-
ticoids to the glass tubes.
Desorption of glucocorticoids from lung tissue
Desorption of glucocorticoids to human lung tissue was
determined as described earlier [3]. Briefly, lung tissue
(1.0 g) was saturated with glucocorticoids for 1 h at 37°C
by shaking in 40 mL Krebs-Ringer-HEPES buffer contain-
ing 0.3 µg/mL of the respective glucocorticoid. After incu-
bation tissue was washed with 2 mL buffer and transferred
into 10.0 mL human plasma (37°C). Again, only glass lab
ware was used for these experiments to exclude any non-
specific binding effects of the highly lipophilic com-
pounds to plastic material. Samples of 1.0 mL were taken
at defined time points. The volume was replaced with
fresh plasma at 37°C. Samples were stored at -20°C until
further analysis.
Sample preparation, HPLC conditions and data analysis
Samples of 1.0 mL (tissue desorption/stability) or 2.0 mL
(tissue adsorption) were mixed with 0.1 mL internal
standard solution and extracted twice with 3 mL diethyl-
ether for 30 min, using a roller mixer, followed by centrif-
ugation (20°C) for 5 min. The organic phase was
separated and evaporated to dryness under a gentle stream
of nitrogen at 25°C. The resulting residue was reconsti-
tuted in 0.2 mL mobile phase. Internal standard (IS) was
amcinonide 3 µg/mL (tissue binding studies) or dexame-
thasone 3 µg/mL (stability studies). Linearity was given
from 10–500 ng/mL glucocorticoid, coefficients of corre-
lation of the calibration curves were at least 0.99.
The HPLC system was a Waters HPLC (Milford, MA) con-
sisting of a 1525 binary pump, an 717plus autosampler
and 2487 dual wavelength absorbance detector set at the
detection wavelength of 254 nm. Data collection and inte-
gration were accomplished using Breeze™ software ver-
sion 3.2. Analysis was performed on a Symmetry C18
column (150 × 4.6 mm I.D., 5 µm particle size, Waters,
MA). Typically, 20 µL of sample were injected and sepa-
rated at a flow rate of 1 mL/min. Gradient elution was per-
formed using water (containing 0.2 % (v/v) acetic acid)
and ACN, starting at 60:40 (v/v) water/ACN increasing
linearly to 29:71 (v/v) water/ACN by 30 min. The assay
was accurate and reproducible. The lower limit of quanti-
tation was 10 ng/mL for all glucocorticoids except cicleso-
nide (20 ng/mL).
Determination of the relative retention time k' of 
glucocorticoids
Relative retention times k' or chromatographic capacity
factors log (k'), respectively, of all new generation gluco-
corticoids in comparison with older glucocorticoids were
determined by a HPLC method based on a former report
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[5]. Briefly, to calculate k' the HPLC retention time on a
C18 reversed-phase column of an individual glucocorti-
coid was related to the retention time of an internal stand-
ard (dexamethasone-21-isonicotinate). Therefore, 10 µL
of the respective glucococorticoid and the internal stand-
ard at a concentration of each 10 µg/mL in methanol were
chromatographed under identical conditions (column
and HPLC system described above). The sample was
injected and separated at a flow rate of 0.7 mL/min. The
mobile phase consisted of methanol, water, ACN and ace-
tic acid at 40:20:5:0.2 (v/v).
Statistical analysis
Mean and mean deviation of the mean were calculated for
all data. Data sets were analysed by one-way ANOVA with
post-hoc Bonferroni's multiple comparison test. Statistical
significance was defined as a significance level of p ≤ 0.05.
Due to the very limited sample number a pre-test was per-
formed to test the normal distribution of the residuals.
Therefore, the residuals of each data group were calculated
and the ratio of range to standard deviation was analysed
according to David et al. [11]. Only when the results were
between the lower and upper critical limits tabulated by
Pearson and Stephens [12] a normal distribution of the
residuals was assumed at a significance level of p ≤ 0.05
and a subsequent ANOVA analysis was performed. On
one data set a reciprocal transformation was performed
for normal distribution of the residuals and subsequent
ANOVA analysis. Due to the limited number of data p val-
ues should be interpreted very cautiously.
Results
Receptor binding kinetics and relative receptor affinity of 
fluticasone furoate (FF)
The receptor binding kinetics to the human lung glucocor-
ticoid receptor revealed that the association kinetics of flu-
ticasone furoate (FF) was distinctly different from those of
fluticasone propionate (FP) and mometasone furoate
(MF) (Table 1). The association rate constant of FF was
statistically significantly higher compared to both MF and
FP (both p ≤ 0.001); thus the specific binding to the recep-
tor occurred more rapidly and to a higher extent com-
pared with all other glucocorticoids. In contrast, the
dissociation rate constant of FF was comparable with that
of FP and MF with no statistically significant difference.
Consequently, the calculated half-lives of the glucocorti-
coid-receptor complexes (t1/2) of FF, FP and MF were all
around 10 hours. Equilibrium dissociation rate constants
(kd) were derived from the association and dissociation
rate constants. The calculated kd of FF was 0.30 nmol/L,
the lowest among the tested glucocorticoids (statistically
significantly lower compared to FP, p ≤ 0.001, and to MF,
p ≤ 0.05). The kd of FP was 0.51 nmol/L, the kd of MF was
determined as 0.41 nmol/L (statistically significantly dif-
ferent, p ≤ 0.05). Based on the equilibrium dissociation
rate constants the relative receptor affinity (RRA) of FF was
calculated as 2989 ± 135. This RRA of FF was significantly
higher compared to FP, p ≤ 0.001, and to MF, p ≤ 0.05.
Correlation between glucocorticoid lipophilicy and 
receptor affinity
The chromatographic capacity factor log (k') reveals an
excellent correlation to the partition coefficient in 1-octa-
nol-water [13,14] which is regarded as a typical parameter
of compound lipophilicity. When the lipophilicity of a
glucocorticoid is expressed as its relative retention time k'
at a reversed-phase HPLC column and correlated with the
relative receptor affinity of the respective compound, a
significant relationship is observed (Figure 2). Potential
fitting of the data according to the equation: y = c * xb.
(with c and b representing constants) revealed a coeffi-
cient of correlation of r = 0.982. This relationship is statis-
tically significant (p < 0.0001). All glucocorticoids
esterified at C21 display higher lipophilicity. However,
these compounds have little or no binding affinity to the
glucocorticoid receptor. They are either inactive metabo-
lites such as beclomethasone-21-monopropionate (21-
BMP) or inactive pro-drugs such as ciclesonide or beclom-
ethasone-17,21-dipropionate which need to be activated
by hydrolysis of the C21 ester [15,16].
Table 1: Results of the kinetic binding experiments of dexamethasone (Dexa), fluticasone furoate (FF), fluticasone propionate (FP) and 
mometasone furoate (MF) to the human lung glucocorticoid receptor. Values given represent mean and mean deviation of the mean 
of three to seven experiments. Binding data of FP and MF are from our previous experiments (Ref. [3]).
Glucocorticoid k1 × 105 (L/[mol/min]) k-1 × 10-4 [1/min] KD [nmol/L] t1/2 [h] RRA
Dexa 10.53 ± 0.35 94.67 ± 5.43 8.80 ± 0.41 1.23 ± 0.04 100 ± 5
FF 37.46 ± 0.73 11.22 ± 0.62 0.30 ± 0.02 10.34 ± 0.59 2989 ± 135
FP 21.17 ± 0.56 10.73 ± 0.65 0.51 ± 0.03 10.82 ± 0.64 1775 ± 130
MF 29.46 ± 1.10 11.82 ± 0.31 0.41 ± 0.03 9.83 ± 0.53 2244 ± 142
Statistically significant differences were observed in the association rate constant k1 (FF versus FP p ≤ 0.001; FF versus MF p ≤ 0.001; FP versus MF p ≤ 
0.001), in equilibrium dissociation rate constant kD (FF versus FP p ≤ 0.001; FF versus MF p ≤ 0.05; FP versus MF p ≤ 0.05) and in the relative receptor 
affinity RRA (FF versus FP p ≤ 0.001; FF versus MF p ≤ 0.05; FP versus MF p ≤ 0.01). No statistically significant difference between FF, MF and FP was 
seen in the dissociation rate constant k-1 and the derived half life of the receptor complex t1/2.Respiratory Research 2007, 8:54 http://respiratory-research.com/content/8/1/54
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Stability of FF in freshly isolated human lung tissue
The stability of FF in the presence in human lung tissue
was monitored over a period of 24 hours at an incubation
temperature of 37°C (Figure 3). The incubations were
performed in the presence and absence of the esterase
inhibitor diclorvos. Indications of instability of the com-
pound are either decreased compound concentrations in
the supernatant in the absence of dichlorvos and/or the
appearance of new peaks in the HPLC chromatograms.
The initial decrease of FF concentration indicated the
binding to the lung tissue pieces. Over the incubation
period, concentrations of FF in the tissue supernatant
were slightly higher in the absence of dichlorvos. No new
peaks were observed in the HPLC chromatograms. No sta-
tistically significant differences were revealed between
concentrations of FF in the presence and absence of the
esterase inhibitor diclorvos at any of the single time
points. Thus, non-specific esterase-catalyzed hydrolysis of
FF did not occur in the presence of human lung tissue.
The enzymatic integrity of the lung tissue was demon-
strated in a simultaneously performed control experiment
with beclomethasone-17,21-dipropionate (BDP). The
results of these control experiments were identical to
those described previously [3]. In the absence of dichlor-
vos BDP concentrations in the supernatant rapidly
decreased and the main metabolite beclomethasone-17-
monopropionate (17-BMP) was detectable at high con-
centrations. Dichlorvos inhibited the decomposition of
BDP and delayed the formation of 17-BMP up to 10 hours
of incubation (data not shown).
Lung tissue binding affinity of fluticasone furoate (FF)
The binding affinity of FF in comparison with MF and FP
to human lung tissue was determined in separate adsorp-
tion and desorption experiments. Control experiments for
non-specific binding to incubation vials were performed
in parallel with the respective glucocorticoid-containing
buffer solutions under identical conditions. These control
experiments revealed no non-specific binding of FF or FP
to the glass incubation vials (Figure 4). A decrease in MF
concentrations over 480 min at 37°C was paralleled by
formation of the degradation product 9,11-epoxy MF as
described earlier [3]. Thus, MF did not display non-spe-
cific binding to glass, but did show chemical instability.
Adsorption of FF to human lung tissue in vitro occurred
rapidly and was complete after about 20 min (data not
shown). After 60 min incubation with the glucocorticoid-
containing buffer at 37°C highest tissue binding was seen
for FF (4.18 ± 0.16 ng/mg) and this was statistically signif-
icantly higher compared to FP (3.39 ± 0.06 ng/mg; p ≤
0.001) and MF (3.65 ± 0.15 ng/mg; p ≤ 0.01) (Figure 5,
left columns). FF also showed greater binding to human
Stability of fluticasone furoate (FF) in human lung tissue sus- pensions of 37°C over 24 hours Figure 3
Stability of fluticasone furoate (FF) in human lung tissue sus-
pensions of 37°C over 24 hours. Symbols represent the 
mean and mean deviation of the mean of four independent 
series of experiments. One incubation mixture contained the 
esterase inhibitor dichlorvos to determine a potential este-
rase mediated decomposition of the parent compound. No 
statistically significant differences between FF concentrations 
in the presence or absence of dichlorvos were observed at 
any of the analysed time points.
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nasal tissue compared with FP in a single experiment with
tissue pooled from 3 donors (data not shown).
The desorption of the glucocorticoids from lung tissue
into human plasma revealed differences between the
compounds (Figure 5, right columns). After 60 min high-
est concentrations of FP (1.55 ± 0.13 ng/mg) and FF (1.21
± 0.23 ng/mg) were still present in the tissue. Remaining
concentrations of FP and FF were not statistically signifi-
cantly different. As reported previously [3], MF was rap-
idly redistributed from the lung tissue into human plasma
and consequently lowest concentrations of mometasone
furoate were detected in the tissue (0.57 ± 0.15 ng/mg).
This was statistically significantly lower compared to FF (p
≤ 0.01) and FP (p ≤ 0.001).
Discussion
Fluticasone furoate (FF) is a newly developed glucocorti-
coid for topical application. In the present investigation
we characterized the receptor binding kinetics and the
binding affinity to human lung tissue of FF in comparison
with other latest generation glucocorticoids. We found
that FF exhibited the highest ever described relative recep-
tor affinity (RRA) of a topical glucocorticoid. The RRA of
FF (2989 ± 135) exceeds the receptor affinities of all cur-
rently used corticosteroids such as mometasone furoate
(MF; RRA = 2244 ± 142), fluticasone propionate (FP; RRA
= 1775 ± 130), the active beclomethasone-17,21-dipropi-
onate (BDP) metabolite beclomethasone-17-monopropi-
onate (17-BMP; RRA = 1345 ± 125), ciclesonide's active
principle (des-Cicle; RRA = 1212, rat receptor data) and
budesonide (RRA = 855). Together with the compound's
high retention in human lung tissue FF incorporates
attributes that are suitable for topical anti-inflammatory
therapy.
The substitution pattern of the steroidal D-ring is impor-
tant for the affinity to the glucocorticoid receptor as well
as for receptor selectivity [17]. For example, the D-ring
substitution confers on MF highly potent glucocorticoid
receptor binding affinity [4,18]. We deduced that D-ring
modifications of MF were so favourable for high affinity
binding to the glucocorticoid receptor that metabolic
hydroxylation at the 6β position or loss of chlorine at the
9 position did not result in complete loss of ligand-bind-
ing properties.
One characteristic of the MF D-ring substitution pattern,
the furoate moiety, is also present in FF. Consistent with
the notion that the esterification of the 17α-OH by furo-
ylation augments affinity we a found remarkably high
RRA for FF that exceeds the RRA of e.g. FP by more than
60 %. This result is supported by recent X-ray crystal struc-
ture data of FF co-crystallized with the glucocorticoid
receptor [19]. These data show the 17α-furoate ester fully
Comparison of concentrations of fluticasone furoate (FF),  fluticasone propionate (FP) and mometasone furoate (MF) in  human lung tissue Figure 5
Comparison of concentrations of fluticasone furoate (FF), 
fluticasone propionate (FP) and mometasone furoate (MF) in 
human lung tissue. The columns represent the mean and 
mean deviation of the mean from four independent experi-
ments. The left columns represent the compound concentra-
tion in tissue before incubation in human plasma. This tissue 
binding of FF was statistically significantly higher compared to 
FP (p ≤ 0.001) and MF (p ≤ 0.01). The right columns display 
the glucocorticoid concentrations remaining in the lung tis-
sue after one hour equilibration with human plasma at 37°C. 
Remaining concentrations of FP and FF were not different 
while statistically significantly lower concentrations of MF 
were retained in the tissue compared to FF (p ≤ 0.01) and FP 
(p ≤ 0.001).
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Control experiment for non-specific adsorption of glucocor- ticoids to incubation vials Figure 4
Control experiment for non-specific adsorption of glucocor-
ticoids to incubation vials. The respective compounds were 
incubated in glass vials over 480 min at 37°C. The concentra-
tion in the supernatant was monitored. The decrease in con-
centrations of mometasone furoate (MF) indicated the 
degradation process of the compound. No adsorption was 
seen for fluticasone propionate (FP) and fluticasone furoate 
(FF). The columns represent the mean and mean deviation of 
the mean from triplicate experiments.
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occupying the lipophilic 17α pocket in the receptor and
additional interactions with the receptor involving the 3-
keto, 11β-hydroxy and 17β-fluoromethylthioester groups
of the fluticasone backbone.
We determined the affinity of FF to the human lung glu-
cocorticoid receptor by separate analysis of the receptor
association and dissociation kinetics. This method is
more precise compared to competition assays, especially
for high affinity glucocorticoids [1]. For FF we observed a
very fast and extensive association with the receptor, with
an association rate constant significantly higher than for
any other glucocorticoid. In contrast, the dissociation rate
constant was almost identical to that of FP. Thus, the dif-
ference between FF and FP is mainly based on the more
rapid and preferential binding of FF to the receptor. This
kinetic behaviour of FF confirms our previous insights
into receptor binding characteristics of high-affinity glu-
cocorticoids [1,3]. FP was the first glucocorticoid with
receptor binding clearly distinct from other compounds.
In comparison with other glucocorticoids it displayed
both a more rapid association and prolonged dissociation
from the receptor [1]. The receptor binding kinetics of MF
disclosed a high association rate constant while its disso-
ciation rate was almost comparable to FP [3]. Thus, fur-
ther increase in receptor affinity for FF was related to an
increase in the association rate constant which is now also
established for this compound.
Interestingly, those glucocorticoids with the highest RRAs
do not comply with the previously described linear rela-
tionship between lipophilicity and receptor affinity [5].
FF, MF and FP reveal clear differences in their RRA, but
their lipophilicity expressed as their relative retention
times at a reversed-phase HPLC column is less different
than their receptor affinities. However, the correlation
between lipophilicity of the active compound and its RRA
is still highly significant, though not linear, if the high
affinity glucocorticoids FF, FP and MF are included into
the analysis. There are glucocorticoids with higher
lipophilicity such as BDP and Cicle, but these compounds
are pro-drugs with virtually no affinity to the receptor.
Both drugs gain activity by ester cleavage in C21 position.
Thereby, however, they lose their high lipophilicity.
Since FF is not a pro-drug, its receptor binding affinity and
thus activity is associated with the entire molecule. The
compound is expected to be stable in the therapeutic tar-
get tissue. This is not necessarily seen for all glucocorti-
coids. We and other research groups recently observed
that MF is not stable in lung tissue or plasma and under-
goes chemical degradation [3,20,21]. We now elucidated
the stability of FF in human lung tissue and found no deg-
radation or metabolism within 24 h at 37°C. The esterase
inhibitor dichlorvos was included in one of the incuba-
tion mixtures in case of an enzyme-catalyzed hydrolysis of
the 17α furoate moiety or of the 17β S-fluoromethyl-car-
bothioate group. Neither did we determine the resulting
metabolites or any other new peaks in the HPLC chroma-
tograms nor did we observe lower FF concentrations in
the tissue supernatant in the absence of dichlorvos. In the
contrary, we found lower FF concentrations in the pres-
ence of the esterase inhibitor, though we do not have a
clear explanation for this phenomenon. We conclude that
there is no indication of instability or chemical modifica-
tion of FF in the presence of enzymatically active human
lung tissue.
Besides a high receptor binding affinity, a prolonged
retention of the glucocorticoid in the lung tissue is a
desired property. We compared the tissue binding behav-
iour of FF with FP and MF. After one hour equilibration of
glucocorticoid-saturated lung tissue pieces with human
plasma at 37°C, we found highest concentrations of FF
and FP compared to MF remaining in the tissue. Obvi-
ously, these compounds have the most favourable tissue
affinity and it should be expected that the distribution of
these glucocorticoids from lung tissue into systemic circu-
lation is slow in vivo. Clinical data confirm this for FP [22].
To conclude, we have characterized the novel glucocorti-
coid fluticasone furoate. Its relative receptor binding affin-
ity exceeds the RRAs of all other currently clinically used
glucocorticoids. Based on the tissue binding experiments
a high retention of fluticasone furoate in human lung tis-
sue is expected. These advantageous binding attributes
may contribute to a highly efficacious profile for FF as a
topical treatment for inflammatory disorders of the respi-
ratory tract.
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